RYZODEG 70/30 PENFILL 70% insulin degludec (rys) / 30% insulin aspart (rys) 100 U/mL solution for injection cartridge Australia - English - Department of Health (Therapeutic Goods Administration)

ryzodeg 70/30 penfill 70% insulin degludec (rys) / 30% insulin aspart (rys) 100 u/ml solution for injection cartridge

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 180 nmol/ml; insulin degludec, quantity: 420 nmol/ml - injection, solution - excipient ingredients: zinc acetate; phenol; hydrochloric acid; sodium chloride; metacresol; water for injections; sodium hydroxide; glycerol - for use in diabetes mellitus in patients aged 6 years and older.

RYZODEG 70/30 FLEXTOUCH 70% insulin degludec (rys) / 30% insulin aspart (rys) 100 U/mL solution for injection cartridge Australia - English - Department of Health (Therapeutic Goods Administration)

ryzodeg 70/30 flextouch 70% insulin degludec (rys) / 30% insulin aspart (rys) 100 u/ml solution for injection cartridge

novo nordisk pharmaceuticals pty ltd - insulin degludec, quantity: 420 nmol/ml; insulin aspart, quantity: 180 nmol/ml - injection, solution - excipient ingredients: water for injections; metacresol; phenol; zinc acetate; sodium hydroxide; glycerol; hydrochloric acid; sodium chloride - for use in diabetes mellitus in patients aged 6 years and older.

XULTOPHY 100/3.6 (- insulin degludec and liraglutide injection, solution United States - English - NLM (National Library of Medicine)

xultophy 100/3.6 (- insulin degludec and liraglutide injection, solution

novo nordisk - insulin degludec (unii: 54q18076qb) (insulin degludec - unii:54q18076qb), liraglutide (unii: 839i73s42a) (liraglutide - unii:839i73s42a) - insulin degludec 100 [iu] in 1 ml - xultophy 100/3.6 is a combination of insulin degludec and liraglutide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use: xultophy 100/3.6 is contraindicated: risk summary based on animal reproduction studies, there may be risks to the fetus from exposure to liraglutide during pregnancy. xultophy 100/3.6 should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. there are no available data with xultophy 100/3.6, insulin degludec or liraglutide in pregnant women to inform a drug associated risk for major birth defects and miscarriage. there are clinical considerations regarding the risks of poorly controlled diabetes in pregnancy [see clinical considerations]. for insulin degludec, rats and rabbits were exposed in animal reproduction studies at 5 times (rat) and 10 times (rabbit) the human exposure at a dose of 0.75 u/kg/day. no adverse outcomes were observed for pregnant ani

LEVEMIR FLEXPEN insulin detemir (rys) 100 U/mL injection cartridge Australia - English - Department of Health (Therapeutic Goods Administration)

levemir flexpen insulin detemir (rys) 100 u/ml injection cartridge

novo nordisk pharmaceuticals pty ltd - insulin detemir, quantity: 100 u/ml - injection, solution - excipient ingredients: glycerol; sodium hydroxide; dibasic sodium phosphate dihydrate; water for injections; hydrochloric acid; zinc acetate; metacresol; phenol; sodium chloride - treatment of diabetes mellitus. (see 'pharmacology' and 'clinical trials.')

LEVEMIR PENFILL insulin detemir (rys) 100 U/mL injection cartridge Australia - English - Department of Health (Therapeutic Goods Administration)

levemir penfill insulin detemir (rys) 100 u/ml injection cartridge

novo nordisk pharmaceuticals pty ltd - insulin detemir, quantity: 100 u/ml - injection, solution - excipient ingredients: phenol; glycerol; dibasic sodium phosphate dihydrate; metacresol; hydrochloric acid; zinc acetate; water for injections; sodium hydroxide; sodium chloride - treatment of diabetes mellitus. (see 'pharmacology' and 'clinical trials.')

NOVOMIX 30 FLEXPEN 3mL 30% soluble insulin aspart (rys) and 70% insulin aspart (rys) crystallised with protamine 300U/3mL injection syringe Australia - English - Department of Health (Therapeutic Goods Administration)

novomix 30 flexpen 3ml 30% soluble insulin aspart (rys) and 70% insulin aspart (rys) crystallised with protamine 300u/3ml injection syringe

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, suspension - excipient ingredients: hydrochloric acid; zinc; metacresol; water for injections; glycerol; sodium chloride; protamine sulfate; sodium hydroxide; dibasic sodium phosphate dihydrate; phenol - treatment of diabetes mellitus.

NOVOMIX 30 PENFILL 3mL 30% soluble insulin aspart (rys) and 70% insulin aspart (rys) crystallised with protamine 300U/3mL injection cartridge Australia - English - Department of Health (Therapeutic Goods Administration)

novomix 30 penfill 3ml 30% soluble insulin aspart (rys) and 70% insulin aspart (rys) crystallised with protamine 300u/3ml injection cartridge

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, suspension - excipient ingredients: zinc; dibasic sodium phosphate dihydrate; protamine sulfate; metacresol; sodium chloride; sodium hydroxide; glycerol; phenol; hydrochloric acid; water for injections - treatment of diabetes mellitus.

INSULIN DEGLUDEC injection, solution United States - English - NLM (National Library of Medicine)

insulin degludec injection, solution

novo nordisk pharma, inc. - insulin degludec (unii: 54q18076qb) (insulin degludec - unii:54q18076qb) - insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus. limitations of use insulin degludec is contraindicated: risk summary available data from one unpublished trial and the published literature with insulin degludec use during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. in a randomized, parallel-group, open-label actively controlled clinical trial that included 91 pregnant women with type 1 diabetes who were administered insulin degludec once daily and insulin aspart, beginning in gestational weeks 8 to 13 or prior to conception, no clear evidence of maternal or fetal risk associated with insulin degludec use was observed (see data ). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). rats and rabbits were exposed to insulin degludec in animal reproduction studies during organogene

TRESIBA- insulin degludec injection, solution United States - English - NLM (National Library of Medicine)

tresiba- insulin degludec injection, solution

novo nordisk - insulin degludec (unii: 54q18076qb) (insulin degludec - unii:54q18076qb) - insulin degludec 100 u in 1 ml - tresiba is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus. limitations of use tresiba is contraindicated: risk summary available data from one unpublished trial and the published literature with tresiba use during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. in a randomized, parallel-group, open-label actively controlled clinical trial that included 91 pregnant women with type 1 diabetes who were administered tresiba once daily and insulin aspart, beginning in gestational weeks 8 to 13 or prior to conception, no clear evidence of maternal or fetal risk associated with tresiba use was observed (see data ). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations ). rats and rabbits were exposed to insulin degludec in animal reproduction studies during organogenesis. pre-and post-implantation losses and vi

TRESIBA FLEXTOUCH insulin degludec (rys) 100 U/mL solution for injection multidose cartridge Australia - English - Department of Health (Therapeutic Goods Administration)

tresiba flextouch insulin degludec (rys) 100 u/ml solution for injection multidose cartridge

novo nordisk pharmaceuticals pty ltd - insulin degludec, quantity: 600 nmol - injection, solution - excipient ingredients: water for injections; zinc; metacresol; phenol; hydrochloric acid; glycerol; sodium hydroxide - treatment of diabetes mellitus in adults, adolescents and children from the age of 1 year.